Durvalumab and Tremelimumab for Pediatric Malignancies

Clinical trial NCT03837899 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03837899
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Pediatric Cancer Solid Tumor Pediatric Hematological Malignancies

Start date: 2019-03-07
Primary completion: 2023-02-28
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.